Economic impact and prevalence of Alzheimer’s disease in a Brazilian capital
DOI:
https://doi.org/10.15448/1983-652X.2017.3.25036Keywords:
doença de Alzheimer, epidemiologia, saúde pública, custos de cuidados de saúde.Abstract
Objectives: To evaluate the economic impact and the prevalence of Alzheimer Disease (AD) in a Brazilian metropolitan city.
Materials and Methods: A cross-sectional, retrospective, descriptive and analytic study using a quantitative approach. Data were collected from the Specialized Dispensing Center for Exceptional Medications in João Pessoa, located in the 1ª Regional Health District in Paraíba, Brazil. The sample comprised 855 patients who received medication to AD. Data were extracted from the national system of management of pharmaceutic assistance, named Horus, and analyzed by descriptive statistic.
Results: The prevalence of AD was higher in patients who were 60 years old or more, especially in the female gender (69.6%). The monthly costs to the state government with medication ranged from R$54.693.19 to R$65.174.19 and annually from R$656.316.00 to R$782.088.00. These findings suggest that AD represent a growing challenge to public health and may impose an important economic impact on the budget of state governments.
Conclusion: This study shows that the dispensation of drugs for the treatment of AD represented a significant cost in the budget of the State Secretariat of Health of Paraíba and there was a high prevalence in the female gender. In addition, it enables the design of public polices directed at prevention, care and management of AD.
References
World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. Geneva: WHO; 2012. 2. Arendt T. Cell cycle activation and aneuploid neurons in Alzheimer’s disease. Mol Neurobiol. 2012;46(1):125-35. https://doi.org/10.1007/s12035-012-8262-0
Burns A, Ilife S. Alzheimer’s disease. BMJ. 2009;338:b158. https:// doi.org/10.1136/bmj.b158
Salawu FK, Umar JT, Olokoba AB. Alzheimer’s disease: a review of recent developments. Ann Afr Med. 2011;10(2):73-9. https://doi. org/10.4103/1596-3519.82057
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–44. https://doi.org/10.1056/NEJMra0909142
Rossor MN, Fox NC, Freeborough PA, Harvey RJ. Clinical features of sporadic and familial Alzheimer’s disease. Neurodegeneration. 1996;5(4):393-7. https://doi.org/10.1006/neur.1996.0052
Chai CK. The genetics of Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2007;22(1):37-41. https://doi.org/10.1177/1533317506295655
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Gestão e Incorporação de Tecnologias em Saúde. Souvenaid para melhora de memória em pacientes com doença de Alzheimer na fase leve. Brasília (DF): Ministério da Saúde; 2014.
Brasil. Ministério da Saúde. Portaria SAS/MS nº 1.298, de 21 novembro de 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Doença de Alzheimer. Brasília (DF): Ministério da Saúde; 2013.
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria nº 1.298, de 21 de novembro de 2013. Brasília (DF): Ministério da Saúde; 2013.
Lima SA. Tratamento farmacológico da doença de Alzheimer. Revista HUPE. 2008;7:78-87.
Brandão CMR, Guerra Júnior AA, Cherchiglia ML, Andrade EIG, Almeida AM, Silva GDS, Queiroz OV, Faleiros DR, Acurcio FA. Gastos do Ministério da Saúde do Brasil com medicamentos de alto custo: uma análise centrada no paciente. Value Health. 2011;14(5):S71-7. https://doi.org/10.1016/j.jval.2011.05.028
Aprahamian I, Martinelli JE, Yassuda MS. Doença de Alzheimer: revisão da epidemiologia e diagnóstico. Rev Bras Clin Med. 2009;7:27-35.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75. https://doi.org/10.1016/j.jalz.2012.11.007
Alzheimer’s Disease International. World Alzheimer Report 2010: the global economic impact of dementia. London: Alzheimer’s Disease International; 2014.
Relatório ADI/Bupa, Demência nas Américas: Custo atual e futuro e prevalência da doença de Alzheimer e outras demências [Internet]. 2013 Out [citado em 2017]. Disponível em: https://www.alz.co.uk/sites/default/files/pdfs/dementia-in-the-americas-BRAZILIANPORTUGUESE.pdf
Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K, Georges J, Gulácsia L, Karpati K. The economic impact of dementia in Europe in 2008: cost estimates from the Eurocode project. Int J Geriatr Psychiatry. 2011;26(8):825-32. https://doi.org/10.1002/gps.2610
Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord. 2006;21(3):175-81. https://doi.org/10.1159/000090733
Alzheimer Society. Rising tide: the impact of dementia on Canadian society. Toronto: Alzheimer Society; 2010.
Alzheimer’s Australia. The dementia epidemic: economic impact and positive solutions for Australia. Canberra: Alzheimer’s Australia; 2003.
Hebert IE, Weuve J, Svherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-83. https://doi.org/10.1212/WNL.0b013e31828726f5
Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand.1987;76(5):465-79. https://doi.org/10.1111/j.1600-0447.1987.
tb02906.x
Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-28.
Viña J, Lloret A. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis. 2010;20(2):S527-33. https://doi.org/10.3233/JAD-2010-100501
Viña J, Borrás C. Women live longer than men: understanding molecular mechanisms offers opportunities to intervene by using estrogenic compounds. Antioxid Redox Signal. 2010;13(3):269-78. https://doi.org/10.1089/ars.2009.2952
Peskind ER, Li G, Shofer JB, Millard SP, Leverenz JB, Yu CE, Raskind MA, Quinn JF, Galasko DR, Montine TJ. Influence of lifestyle modifications on age-related free radical injury to brain.JAMA Neurol. 2014;71(9):1150-4. https://doi.org/10.1001/jamaneurol.2014.1428
Paraíba. Governo do Estado. Controladoria Geral do Estado da Paraíba. Portal transparência: consulta despesas. [Internet]. Paraíba; 2014 [citado em 2017]. Disponível em: http://transparencia.pb.gov.br/despesas/consulta-despesa
Vale FAC, Corrêa Neto Y, Bertolucci PHF, Machado JCB, Silva DJ, Allam N, Balthazar MLF. Tratamento da doença de Alzheimer. Dement Neuropsychol. 2011;5(1):34-48.
Álvarez A, Linares C, Masliah E. Combination drug therapy for the treatment of Alzheimer›s disease. Eur Neurol Rev. 2012;7(2): 92-102. https://doi.org/10.17925/ENR.2012.07.02.92
Veras RP, Caldas CP, Dantas SB, Sancho lG, Sicsú B, Motta lB, Cardinale C. Avaliação dos gastos com o cuidado do idoso com demência. Rev Psiquiatr Clín. 2007;34(1):5-12. https://doi.org/10.1590/S0101-60832007000100001
Gutierrez BAO, Silva HS, Guimaraes C, Campino AC. Impacto econômico da doença de Alzheimer no Brasil: é possível melhorar a assistência e reduzir custos? Ciênc Saúde Coletiva. 2014; 19(11):4479-86. https://doi.org/10.1590/1413-812320141911.03562013
Downloads
Published
Issue
Section
License
COPYRIGHT
The submission of originals to Ciência & Saúde implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Ciência & Saúde as the site of original publication.
CREATIVE COMMONS LICENSE
As this journal is open access, the articles are allowed free use in scientific and educational applications, with citation of the source.
According to the type of Creative Commons License (CC-BY 4.0) adopted by Ciência & Saúde , the user must respect the requirements below.
You are free to:
Share — copy and redistribute the material in any medium or format.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
However, only under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests Ciência & Saúde endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
For more details on the Creative Commons license, please follow the link in the footer of this website.
